Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Acorda Therapeutics (ACORQ) has shared an announcement.
Acorda Therapeutics, Inc. has finalized an asset sale to Merz Pharmaceuticals for $185 million, after filing for Chapter 11 bankruptcy. The company’s equity will be canceled, with no distributions to equity holders, as a Liquidation Plan takes effect. A Liquidating Trustee will manage the sale proceeds and handle the company’s dissolution, representing a significant shift in the company’s trajectory and a cautionary tale for investors in similar situations.
Learn more about ACORQ stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue